24/7 Market News Snapshot 24 June, 2025 – Sangamo Therapeutics, Inc. Common Stock (NASDAQ:SGMO)
DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NASDAQ:SGMO) are discussed in this article.
Sangamo Therapeutics, Inc. (SGMO) has experienced a notable surge in stock price, opening at $0.452 and currently trading at $0.483, reflecting an increase of 11.81% during today’s session. This uptick follows a previous close of $0.432 and aligns with a trading volume of 14.37 million shares, indicating a surge in investor interest. The strong price movement above the opening level suggests bullish sentiment within the market, with the next resistance level potentially lying around $0.50. Traders are advised to monitor volume trends and potential reversal patterns as market dynamics unfold.
In conjunction with its market performance, Sangamo has also reported positive topline results from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a novel gene therapy targeting Fabry disease in adults. The trial’s findings revealed a positive average annualized eGFR slope of 1.965 mL/min/1.73m²/year at the 52-week mark, based on data from all 32 participants receiving a single dose. This significant efficacy, which exceeded expectations, has been sustained over a follow-up period extending to 104 weeks.
The FDA has recognized these findings, agreeing that the average eGFR slope may be utilized as an intermediate clinical endpoint under the Accelerated Approval pathway, positioning isaralgagene civaparvovec favorably for potential regulatory approval, with a Biologics License Application submission expected in the first quarter of 2026.
The STAAR study included both enzyme replacement therapy (ERT) recipients and treatment-naïve patients, showcasing improvements across secondary endpoints, including quality of life metrics and disease severity assessments. Dr. Nathalie Dubois-Stringfellow, Chief Development Officer of Sangamo, expressed enthusiasm for the results, which may usher in new care standards for Fabry disease while acknowledging the contributions of participants and investigators. With further analyses and presentations anticipated at forthcoming medical meetings, Sangamo is dedicated to driving isaralgagene civaparvovec through the regulatory process and exploring potential commercialization partnerships.